<DOC>
	<DOCNO>NCT01236118</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability LY2439821 subcutaneously administer 48 week Japanese participant rheumatoid arthritis complete Study I1F-JE-RHAL ( NCT01253265 ) .</brief_summary>
	<brief_title>A Study LY2439821 Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Participants receive 7 injection LY2439821 subcutaneously 30 , 80 , 180mg dose cohort , 11 injection 240mg load dose/120mg onceaweek maintenance dose group , complete followup period ( 14 week ) Study I1FJERHAL ( ( NCT01253265 ) . Ambulatory male female participant . Male participant : Agree use reliable method birth control study include barrier contraceptive monogamous relationship partner child bearing . Female participant : Are woman test negative pregnancy time entry base pregnancy test breast feeding . Women child bear potential must agree use reliable method birth control study . Participants treated methotrexate ( MTX ) throughout Study I1FJERHAL ( NCT01253265 ) . Bucillamine , sulfasalazine and/or hydroxychloroquine allow administer addition MTX . In case , participant need stable dose drug ( ) throughout Study I1FJERHAL ( NCT01253265 ) I1FJERHAM . Participants give write informed consent approve Sponsor Institutional Review Board ( IRB ) govern investigational site . Participants , Study I1FJERHAL ( NCT01253265 ) , safety event include recent , ongoing , serious infection , serious drug reaction , adverse event ( AE ) cause discontinuation treatment , opinion investigator pose unacceptable risk participation study . Participants follow abnormality clinical laboratory test result Week 26 Study I1FJERHAL ( NCT01253265 ) : Absolute neutrophil count &lt; 1000 cells/microliters ( μL ) ; Lymphocyte count &lt; 500 cells/μL ; White Blood Cells ( WBC ) count &lt; 2000 cells/μL</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>